Michael speaks with Tim Wu, the Columbia law professor and author of The Age of Extraction, about how media and tech platforms learned to harvest our attention, why convenience is among the most powerful forces of our time, and what the easy option can take from us. They discuss:(00:00) Cold open(01:12) Selling attention, from 1833 to now(07:46) Why phones are changing human evolution(16:20) Why ads adapt to every backlash(18:00) Attention merchants vs. extractors(25:48) Easiest wins: the power of

Genmab and AbbVie's investigational frontline Epkinly (epcoritamab) combination cut progression-or-death hazard 51% versus R-CHOP in lymphoma patients with IPI scores of 3–5; it did not face Polivy's approved regimen. Vaxcyte's VAX-31 met its pivotal immune-response framework, with two serotypes clearing only a looser threshold against Merck's CAPVAXIVE—not proof of disease prevention. Deals span GE HealthCare–SOFIE and PET tracer FAPI-74, Shionogi–IntraBio and AQNEURSA in rare

He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out.

What is the state of the debate over evolution and intelligent design in the UK? And how will Discovery Institute's new Cambridge initiative impact the debate going forward? On this ID The Future, host Andrew McDiarmid welcomes fellow Scotsman Dr. Alistair McKitterick, a Consulting Fellow at the Center for Science & Culture’s Whewell Center in Cambridge and a Program Director at London School of Theology. The pair will discuss how Alistair got interested in intelligent design, his work at the

Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Corxel's Bo Liang calls GLP-1's leap to bariatric-surgery-level efficacy the biggest surprise in obesity medicine.

Each week, join Editor-in-Chief Brad Maron, along with cohosts Mercedes Carnethon and Jane Wilcox for the new iteration of Circulation on the Run. This week, Brad and Merci welcome our own Jane Wilcox to discuss a new article type in Circulation: Clinical Problem-Solving. She also discusses her own Clinical Problem-Solving article "When VT Storm, PET Positivity, and a Negative Endomyocardial Biopsy Collide." Then Brad and Merci speak with Associate Editor Maria Kontaridis as she discusses her

🧠 JOIN THE GIANT'S SHOULDER FAMILYBecome a YouTube Member for exclusive episodes, early access + ad-free viewing 👇https://www.youtube.com/@thegiantsshoulder/joinAlexander Beiner is the writer who volunteered as a guinea pig for the world's first extended-state DMT trial. At Imperial College London, he was one of eleven people kept on a continuous DMT drip for thirty minutes. He is a co-Executive Director of Breaking Convention, Europe's largest psychedelic conference, and the author of

In this episode of The BioHub Podcast, Ben sits down with Dr. Inder Kaul, Chief Medical Officer at Draig Therapeutics, to discuss the evolution of neuropsychiatric drug development and what it takes to translate novel neuroscience into meaningful medicines for patients.Inder brings decades of global clinical development experience, most recently playing a key role in the development of Cobenfy at Karuna Therapeutics and Bristol Myers Squibb - one of the most significant advances in schizophrenia

Lilly's retatrutide detail reveals that adverse-event discontinuations peaked below the top dose, while Jaypirca gains first-line CLL and SLL approval for adults without a known 17p deletion. Novartis agrees to $575 million upfront for Abogen's autoimmune RNA program, and Sanofi-Regeneron expands its long-acting antibody partnership. Ovarian-cancer datasets, Mirum's hepatitis D results and uniQure's Huntington's filing show why patient populations and control groups matter. CMS

Jason Hafler shares an overview of the corporate side of the venture world. He describes the unique value that he believes a corporate based VC can bring to the companies it invests in. Plus, his description of cases where investments might ultimately be a good fit for BD and/or M&A within the company, and why an investment might ultimately land at a different suitor.

Dr. Don and Professor Ben talk about the risks Dr. Don - risky ☣️ Professor Ben - risky ☣️ Fulminant Bacillus cereus food poisoning with fatal multi-organ failure | BMJ Case Reports Predictive Model for Growth of Bacillus cereus at Temperatures Applicable to Cooling of Cooked Pasta - Juneja - 2019 - Journal of Food Science - Wiley Online Library Heat-stable toxin production by strains of Bacillus cereus, Bacillus firmus, Bacillus megaterium, Bacillus simplex and Bacillus licheniformis | FEMS

Welcome back to another episode of PASCV: Gone Viral!We return with part 2 of 2 of our tick-borne virus series with our hosts Kaisha & Saina, who are joined by Drs. Ryan Relich, Muhammad Morshed, and Kyle Rodino, as they continue their discussion on various tick-borne diseases, their expanding geographical range, and challenges with diagnostics, surveillance, and clinical impact. Interested in becoming a member of PASCV?https://www.pascv.org/general/register_member_type.aspCheck out our

Recalls make the headlines. But the real cost of poor quality never makes the press release — it hides in rework, investigations, remediation, and the launches that never happen.• The costs nobody puts on the recall announcement• Rework, investigations, and remediation: the real math• How poor quality taxes every future product launch• Making the business case for quality investmentNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on

In this classic episode of Weirdhouse Cinema, Rob and Joe discuss the 1988 horror comedy creature feature Killer Klowns From Outer Space, produced by the Chiodo brothers and starring Grant Cramer, Suzanne Snyder, John Allen Nelson and John Vernon. (originally published 10/3/2025)See omnystudio.com/listener for privacy information.

21 CFR Part 4 sets the CGMP requirements for combination products. If your product has a drug and a device in it, you're on the hook for both sets of regulations. In this video, I walk through Part 4 Subpart A section by section: the scope, the key definitions, which CGMPs apply, and the two ways to comply, including the streamlined approach under 4.4(b).Updated for February 2026, when the device side moved to the QMSR and ISO 13485, plus the new medical gas provisions.Working on your first

In this episode of The BioHub by Avetix, I’m joined by Eran Seger, CEO and Co-Founder of Protai.Eran shares his unique journey into biotech and the inspiration behind founding Protai, where the team is combining proteomics and AI to better understand disease biology and improve how new medicines are discovered.We discuss what makes Protai’s platform different, the realities of being a first-time founder and CEO, the challenge of bringing technology and biotech teams together, and where Eran believes

Trays are piling up. Staffing is stretched thin. Quality issues keep popping up. When everything feels urgent, how do you know what to tackle first? In this episode of "Lead with Confidence," Betty Casey from Surgical Solutions breaks down how data can help Sterile Processing leaders cut through the noise and make more confident, informed decisions. Whether it's tracking tray backlogs, improving scanning compliance, identifying workflow gaps, or getting your team invested in the numbers, Betty

Planetterrian Daily🌍 Planetterrian Daily - Science, Longevity & Health Discoveries A protein known as the glue holding cells together also helps epithelial cells swallow dead neighbors in zebrafish and mouse embryos. Top 15 Science & Health Discoveries ... Sources: sciencedaily.com · reddit.com · phys.org · smallcaps.com.au · directorstalkinterviews.com · dongascience.com AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. 🎬 Watch on

Dr. Beth Shapiro, PhD, is an evolutionary biologist and Chief Science Officer at Colossal Biosciences. Her work focuses on de-extinction and wildlife conservation efforts. We discuss genetic differences among humans, and how ancient DNA and modern embryology are being used to de-extinct and protect woolly mammoths, dodo birds, and dire wolves, as well as to help conserve endangered species. We also explore the ethical implications of de-extinction and how synthetic biology can help build a more bio

We’re easing you into Halloween season with an episode about bats. There’s a silent serial killer decimating little brown bats as they hibernate. White nose syndrome has driven populations across the U.S. to almost the brink of extinction over the last decade. But recently, conservation biologist Giorgia Auteri and her team noticed several genetic mutations in the survivors. These mutations could explain how natural selection has shifted the existing population – and inform conservation efforts in